Table 1.
Distribution of demographic and clinical characteristics of patients diagnosed with adenocarcinoma or squamous cell carcinoma in the original AJCC 3rd and 6th staging editions and recoded 7th edition.
Figure 1.
Kaplan-Meier analysis of patients with and without COPD among those treated with surgery alone.
Log-rank tests were used to assess the difference in survival probabilities of two groups.
Table 2.
Association of each comorbid condition and NSCLC survival when the patient sample was restricted to patients receiving surgery without radiation or chemotherapy.
Table 3.
Comparison of patient information in good prognosis (those survived more than 5 years) and poor prognosis (those survived less than 2 years) groups when the patient sample was restricted to patients receiving surgery without radiation or chemotherapy.
Figure 2.
Comprehensive prognostic model for lung adenocarcinoma.
Patient survival at 60 months for the total population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars. Model coefficients used to determine the Hazard Score for each patient are shown on the forest plot (right). A: AJCC 3rd Staging Edition; B: AJCC 6th Staging Edition; C: AJCC 7th Staging Edition.
Figure 3.
Comprehensive model for squamous cell lung carcinoma.
Model coefficients used to determine the Hazard Score for each patient are shown on the forest plot (right). Patient survival at 24 months for the total population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars. A: AJCC 3rd Staging Edition; B: AJCC 6th Staging Edition; C: AJCC 7th Staging Edition.
Figure 4.
An example of output from the web-based version of the comprehensive prognostic model.
Given the patient information submitted by the user (left), the web-based tool will estimate survival for each treatment category using the survival observed for patients of a particular treatment modality and similar Hazard Score (right).